Plemel Jason R, Juzwik Camille A, Benson Curtis A, Monks Michael, Harris Chelsea, Ploughman Michelle
Department of Clinical Neurosciences and the Hotchkiss Brain Institute, University of Calgary, Canada.
Department of Neurology and Neurosurgery, Montréal Neurological Institute, Canada.
Mult Scler. 2015 Oct;21(12):1485-95. doi: 10.1177/1352458515601513. Epub 2015 Aug 18.
Anti-oxidant compounds that are found in over-the-counter (OTC) supplements and foods are gaining interest as treatments for multiple sclerosis (MS). They are widely used by patients, sometimes without a clear evidence base.
We conducted a systematic review of animal and clinical research to determine the evidence for the benefits of OTC anti-oxidants in MS.
Using predefined criteria, we searched key databases. Two authors scrutinized all studies against inclusion/exclusion criteria, assessed study risk-of-bias and extracted results.
Of the 3507 titles, 145 met criteria and included compounds, α(alpha)-lipoic acid (ALA), anti-oxidant vitamins, Ginkgo biloba, quercetin, resveratrol and epigallocatechin-3-gallate (ECGC). The strongest evidence to support OTC anti-oxidants was for compounds EGCG and ALA in animal models; both consistently showed anti-inflammatory/anti-oxidant effects and reduced neurological impairment. Only vitamin E, Ginkgo biloba and ALA were examined for efficacy in pilot clinical trials with either conflicting evidence or evidence of no benefit.
OTC anti-oxidants EGCG and ALA show the most consistent benefit, however only in preclinical studies. There is no evidence that they alter MS relapses or progression. Future work should focus on testing more of these therapies for clinical efficacy before recommending them to MS patients.
非处方(OTC)补充剂和食物中含有的抗氧化化合物作为治疗多发性硬化症(MS)的方法正受到关注。患者广泛使用这些物质,有时并无明确的证据基础。
我们对动物和临床研究进行了系统评价,以确定非处方抗氧化剂对MS有益的证据。
使用预定义标准检索关键数据库。两位作者对照纳入/排除标准仔细审查所有研究,评估研究的偏倚风险并提取结果。
在3507篇标题中,145篇符合标准,涉及的化合物有α-硫辛酸(ALA)、抗氧化维生素、银杏、槲皮素、白藜芦醇和表没食子儿茶素-3-没食子酸酯(ECGC)。支持非处方抗氧化剂的最有力证据是动物模型中的化合物ECGC和ALA;两者均始终显示出抗炎/抗氧化作用并减轻神经功能损害。在初步临床试验中,仅对维生素E、银杏和ALA的疗效进行了研究,证据相互矛盾或无益处。
非处方抗氧化剂ECGC和ALA显示出最一致的益处,但仅在临床前研究中。没有证据表明它们能改变MS的复发或进展。未来的工作应集中在对更多这些疗法进行临床疗效测试,然后再向MS患者推荐。